Shares of Valeant Pharmaceuticals (VRX) were higher Monday on news that company named a new CFO. The Canadian drugmaker named Paul Herendeen, former Zoetis (ZTS) CFO, to fill the position. Herendeen replaces Robert Rosiello, who will remain at Valeant as Executive Vice President, Corporate Development and Strategy. CEO Joseph Papa said in a statement that Herendeen's prior experience, strong operational focus and disciplined approach to financial management make him the ideal choice to lead the company's finance function as it executes on plans to stabilize and transform the company.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.